AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37669480
Drug: Selinexor (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selinexor (80 mg oral, once weekly)
Trial: 37669842
Drug: Monthly medication
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly medication costs
Trial: 37669842
Drug: Suboptimal medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suboptimal medication adherence
Trial: 37670005
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of glucose and high-sensitivity cardiac troponin T (hs-cTnT)
Trial: 37670005
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of glucose and high-sensitivity cardiac troponin I (hs-cTnI)
Trial: 37670005
Drug: Dual-marker strategy
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual-marker strategy (glucose < 7 mmol/L and hs-cTnT < 5/hs-cTnI < 4 ng/L)
Trial: 37670194
Drug: Early drain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early drain removal (EDR) on postoperative day 3 if serous and drain bilirubin level < 3 mg/dl (3×3 rule)
Trial: 37670194
Drug: Routine drain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine drain removal (RDR) based on drain output being serous and < 100 ml
Trial: 37670234
Drug: Individual characteristics
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual characteristics (e.g., CSF level of A[Formula: see text]).
Trial: 37670579
Drug: Ciprofibrate 100
RxNorm normalized name: ciprofibrate 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofibrate 100 mg/d for 5 weeks
Trial: 37670901
Drug: HP-β-CD 1500
RxNorm normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP-β-CD 1500 mg/kg
Trial: 37670901
Drug: HP-β-CD 2000
RxNorm normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP-β-CD 2000 mg/kg
Trial: 37670901
Drug: HP-β-CD 2500
RxNorm normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP-β-CD 2500 mg/kg
Trial: 37670901
Drug: HP-β-CD (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HP-β-CD (all doses)
Trial: 37671748
Drug: avelumab combined
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: avelumab combined with sacituzumab govitecan (anti-Trop-2/topoisomerase inhibitor conjugate)
Trial: 37672016
Drug: Aripiprazole 2-Month
RxNorm normalized name: aripiprazole 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aripiprazole 2-Month Ready-to-Use 960 mg
Trial: 37672083
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy (aPTD) combined with full-mouth disinfection
Trial: 37672083
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy (aPTD)
Trial: 37672197
Drug: Vericiguat 2.5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vericiguat 2.5-10 mg
Trial: 37672268
Drug: Valsartan (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan (80 mg/d for children <35 kg, 160 mg/d for children ≥35 kg, 320 mg/d for adults)
Trial: 37672548
Drug: Weekly primaquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly primaquine (PQ8W) at a dose of 0.75 mg/kg for 8 weeks plus dihydroartemisinin piperaquine or chloroquine
Trial: 37672548
Drug: Weekly primaquine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly primaquine (PQ8W)
Trial: 37672566
Drug: Drug-releasing intratumoral
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug-releasing intratumoral microdevices (IMDs) used during tumor resection for 2 to 3 hours.
Trial: 37672566
Drug: Drug-releasing intratumoral
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug-releasing intratumoral microdevices (IMDs) used during tumor resection.
Trial: 37672598
Drug: Functional Assessment
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional Assessment of Cancer Therapy-General (FACT-G)
Trial: 37672694
Drug: Atezolizumab (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atezolizumab (1200 mg for patients ≥18 years; 15 mg/kg with a 1200 mg cap for patients <18 years) administered intravenously once every 21 days
Trial: 37673112
Drug: Radical cytoreductive
RxNorm normalized name: Campsis radicans flower extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radical cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)
Trial: 37673112
Drug: Neoadjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant therapy followed by surgery
Trial: 37673453
Drug: 7-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day course of antibiotic treatment
Trial: 37673453
Drug: 14-day course
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day course of antibiotic treatment
Trial: 37673858
Drug: Triplet maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triplet maintenance therapy (olaparib, pembrolizumab, bevacizumab)
Trial: 37674214
Drug: Flexible outpatient
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flexible outpatient treatment model
Trial: 37674358
Drug: Plasminogen, human-tvmh
RxNorm normalized name: plasminogen, human-tvmh
DrugBank: Plasminogen (DB16701)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasminogen, human-tvmh (6.6 mg/kg administered every 2-5 days for 48 weeks and every 1-7 days for up to 124 weeks)
Trial: 37674711
Drug: 30-min daily
RxNorm normalized name: lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 30-min daily bright blue-green light (12,000 lux)
Trial: 37674777
Drug: High-intensity interval
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-intensity interval training (spinning) for 12 weeks, three times weekly
Trial: 37675038
Drug: Controlled-release carbamazepine
RxNorm normalized name: carbamazepine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release carbamazepine (CBZ-CR) monotherapy
Trial: 37675613
Drug: Rivaroxaban 20
RxNorm normalized name: rivaroxaban 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rivaroxaban 20 mg daily for 180 days
Trial: 37675613
Drug: Standard-of-care anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care anticoagulation (warfarin or low-molecular-weight heparin) for 180 days
Trial: 37675828
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for recent HCV infection
Trial: 37675901
Drug: Longer cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longer cumulative duration of antiretroviral therapies
Trial: 37676105
Drug: Normal CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal CC
Trial: 37676110
Drug: Apatinib combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib combined with dose-dense paclitaxel and carboplatin (Apa+ddTCb)
Trial: 37676110
Drug: Dose-dense paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dose-dense paclitaxel plus carboplatin (ddTCb)
Trial: 37676200
Drug: S-ICD (Subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ICD (Subcutaneous Implantable Cardioverter-Defibrillator)
Trial: 37676259
Drug: Tremelimumab in
RxNorm normalized name: tremelimumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tremelimumab in combination with durvalumab
Trial: 37676612
Drug: Posaconazole 300
RxNorm normalized name: posaconazole 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Posaconazole 300 mg IV/300 mg orally once daily (twice daily on day 1)
Trial: 37676612
Drug: Voriconazole 4
RxNorm normalized name: voriconazole 40 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voriconazole 4 mg/kg IV twice daily/200 mg orally twice daily (6 mg/kg on day 1)
Trial: 37676715
Drug: Home-based exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based exercise prehabilitation program (details on dosage and duration not available)
Trial: 37677000
Drug: Melanocortin Pan-Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melanocortin Pan-Agonist PL9643, dosage and duration not available
Trial: 37677918
Drug: Cadonilimab 6
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab 6 mg/kg intravenously every 2 weeks in cohort A
Trial: 37677918
Drug: Cadonilimab 6
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab 6 mg/kg intravenously every 2 weeks in cohort B
Trial: 37677918
Drug: Cadonilimab 6
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadonilimab 6 mg/kg intravenously every 2 weeks in cohort C
Trial: 37678222
Drug: Taurolidine/heparin catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurolidine/heparin catheter lock solution (13.5 mg/ml taurolidine and 1000 units/ml heparin)
Trial: 37678222
Drug: Heparin control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin control catheter lock solution (1000 units/ml)
Trial: 37678222
Drug: Taurolidine/heparin catheter
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurolidine/heparin catheter lock solution
Trial: 37678222
Drug: Taurolidine/heparin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurolidine/heparin and Heparin
Trial: 37678222
Drug: Taurolidine/heparin
RxNorm normalized name: TAUROLIDINE/HEPARIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurolidine/heparin
Trial: 37678257
Drug: Calpain inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calpain inhibitors
Trial: 37678277
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with docetaxel, oxaliplatin, and capecitabine (DOX regimen)
Trial: 37678277
Drug: Neoadjuvant chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant chemotherapy with oxaliplatin plus capecitabine (XELOX regimen)
Trial: 37679276
Drug: gp145 C.6980
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gp145 C.6980 high dose (300 mcg), n = 25
Trial: 37679276
Drug: gp145 C.6980
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gp145 C.6980 low dose (100 mcg), n = 15
Trial: 37679276
Drug: gp145 C.6980
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gp145 C.6980 (both doses), n = 40
Trial: 37679536
Drug: Mild CKD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild CKD (eGFR=60-89 mL/min/1.73 m²)
Trial: 37679712
Drug: Remote monitoring
RxNorm normalized name: iodine
DrugBank: Iodine (DB05382)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remote monitoring intervention for managing heart failure, including tracking patients' weight and diuretic adherence.
Trial: 37679723
Drug: CGRP infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CGRP infusion (1.5 µg/min) over 20 min
Trial: 37680795
Drug: Anti-cytokine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-cytokine treatment (tocilizumab in 53 patients, anakinra in 27 patients)
Trial: 37680795
Drug: No anti-cytokine
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No anti-cytokine treatment (77 patients)
Trial: 37680795
Drug: Anti-cytokine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-cytokine treatment
Trial: 37680942
Drug: CT017 CAR
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT017 CAR T cells at a dose of 250 × 10^6
Trial: 37681568
Drug: Eicosapentaenoic acid
RxNorm normalized name: eicosapentaenoic acid
DrugBank: Icosapent (DB00159)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eicosapentaenoic acid plus docosahexaenoic acid (3.36 g/d) for 30 months
Trial: 37682405
Drug: IND 75
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IND 75 µg
Trial: 37682405
Drug: IND 150
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IND 150 µg
Trial: 37682573
Drug: Adaptive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive treatment with varenicline
Trial: 37682573
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with varenicline
Trial: 37682573
Drug: Adaptive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive treatment with nicotine patches
Trial: 37682573
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with nicotine patches
Trial: 37682920
Drug: Ablative fractional
RxNorm normalized name: LIVER FRACTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ablative fractional CO2 laser treatment
Trial: 37682953
Drug: Abemaciclib pre-operatively
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abemaciclib pre-operatively for 4.5 days at twice daily dosing
Trial: 37682953
Drug: Abemaciclib therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Abemaciclib therapy along with temozolomide
Trial: 37683037
Drug: Neoadjuvant pembrolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant pembrolizumab (anti-PD-1), 2 doses
Trial: 37683048
Drug: Single plating
RxNorm normalized name: platinic chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single plating (standard locally available implant)
Trial: 37683098
Drug: Long-Term Oxygen
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-Term Oxygen Therapy (LTOT)
Trial: 37683122
Drug: Treatment strategies
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment strategies for pulmonary exacerbations in pediatric cystic fibrosis patients
Trial: 37683234
Drug: Brexpiprazole Combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brexpiprazole Combination Therapy
Trial: 37683276
Drug: FF-10850 +
RxNorm normalized name: FF-10501
DrugBank: FF-10501-01 (DB17554)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF-10850 + anti-PD-1 antibody
Trial: 37683518
Drug: Metformin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin therapy plus standard care
Trial: 37683686
Drug: upadacitinib 30
RxNorm normalized name: upadacitinib 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: upadacitinib 30 mg once daily
Trial: 37683799
Drug: 3 M True
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3 M True Definition Intraoral Scanner or 3 M Lava Chairside Oral Scanner
Trial: 37684332
Drug: Nasal-spraying Bacillus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal-spraying Bacillus spores (LiveSpo Navax) containing 5 billion of Bacillus subtilis and B. clausii spores in 5 mL.
Trial: 37684373
Drug: TRC105 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRC105 monotherapy (10 mg/kg)
Trial: 37684682
Drug: Link work
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Link work intervention (treatment as usual plus a link worker intervention) consisting of six sessions over 9 months.
Trial: 37684682
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (control).
Trial: 37685975
Drug: Citrus and
RxNorm normalized name: Chloroxylenol 0.003 g in 1 mL TOPICAL SOAP [Clorox Citrus and Sage Dish]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrus and pomegranate complex (CPC) 500 mg
Trial: 37686032
Drug: Runcaciguat 1
RxNorm normalized name: Runcaciguat
DrugBank: Runcaciguat (DB16700)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Runcaciguat 1 mg/kg/bid
Trial: 37686032
Drug: Runcaciguat 3
RxNorm normalized name: Runcaciguat
DrugBank: Runcaciguat (DB16700)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Runcaciguat 3 mg/kg/bid
Trial: 37686032
Drug: Runcaciguat 10
RxNorm normalized name: Runcaciguat
DrugBank: Runcaciguat (DB16700)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Runcaciguat 10 mg/kg/bid
Trial: 37689018
Drug: High-dose (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (60 Gy) IMRT with weekly cisplatin
Trial: 37689323
Drug: Active transcranial
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active transcranial direct current stimulation (a-tDCS) on left dorsolateral prefrontal cortex (l-DLPFC), n=34
Trial: 37689323
Drug: Sham transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham transcranial direct current stimulation (s-tDCS) on l-DLPFC, n=17
Trial: 37689749
Drug: High-dose carboplatin-thiotepa-cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose carboplatin-thiotepa-cyclophosphamide
Trial: 37689749
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy (ddAC only or ddAC-capecitabine/decetaxel [CD] or ddAC-carboplatin/paclitaxel [CP])
Trial: 37689749
Drug: High-dose alkylating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose alkylating chemotherapy
Trial: 37689822
Drug: Pharmacogenetic testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenetic testing panel for 26 drugs
Trial: 37689822
Drug: Pharmacogenetic testing
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacogenetic testing panel for aripiprazole and serotonin or serotonin-norepinephrine reuptake inhibitors
Trial: 37690061
Drug: Lorundrostat 100
RxNorm normalized name: Lorundrostat
DrugBank: Lorundrostat (DB18957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorundrostat 100 mg once daily
Trial: 37690061
Drug: Lorundrostat 50
RxNorm normalized name: Lorundrostat
DrugBank: Lorundrostat (DB18957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorundrostat 50 mg once daily
Trial: 37690061
Drug: Lorundrostat 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorundrostat 12.5 mg once daily
Trial: 37690061
Drug: Lorundrostat 25
RxNorm normalized name: Lorundrostat
DrugBank: Lorundrostat (DB18957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorundrostat 25 mg twice daily
Trial: 37690061
Drug: Lorundrostat 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorundrostat 12.5 mg twice daily
Trial: 37690061
Drug: Lorundrostat 100
RxNorm normalized name: Lorundrostat
DrugBank: Lorundrostat (DB18957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorundrostat 100 mg once daily (participants without suppressed PRA)
Trial: 37690061
Drug: Lorundrostat 50
RxNorm normalized name: Lorundrostat
DrugBank: Lorundrostat (DB18957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorundrostat 50 mg once daily vs Placebo
Trial: 37690061
Drug: Lorundrostat 100
RxNorm normalized name: Lorundrostat
DrugBank: Lorundrostat (DB18957)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorundrostat 100 mg once daily vs Placebo
Trial: 37690784
Drug: High-dose (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose (40 mg/day)
Trial: 37690784
Drug: Low-dose (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose (20 mg/day)
Trial: 37690874
Drug: CHIKV VLP
RxNorm normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHIKV VLP vaccine in seropositive recipients
Trial: 37690874
Drug: CHIKV VLP
RxNorm normalized name: chikungunya virus antigen, recombinant Senegal strain 37997
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHIKV VLP vaccine in seronegative recipients
Trial: 37691092
Drug: App-based management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: App-based management system for chronic pain patients with SCS implants
Trial: 37691092
Drug: Monthly online
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly online follow-ups
Trial: 37691144
Drug: Surgical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical treatment with connective tissue graft (CTG) and individualized supportive peri-implant care (SPC) program
Trial: 37691729
Drug: Golimumab (GLM)
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab (GLM) 50 mg
Trial: 37691729
Drug: Golimumab (GLM)
RxNorm normalized name: Golimumab
DrugBank: Golimumab (DB06674)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Golimumab (GLM) 100 mg